Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel P. Cahill, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Daniel Cahill and Anthony Iafrate.
Connection Strength

2.050
  1. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
    View in: PubMed
    Score: 0.210
  2. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathol Commun. 2018 10 17; 6(1):106.
    View in: PubMed
    Score: 0.203
  3. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
    View in: PubMed
    Score: 0.201
  4. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115.
    View in: PubMed
    Score: 0.185
  5. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784.
    View in: PubMed
    Score: 0.167
  6. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41.
    View in: PubMed
    Score: 0.166
  7. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011 Dec 13; 20(6):810-7.
    View in: PubMed
    Score: 0.126
  8. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007 Apr 01; 13(7):2038-45.
    View in: PubMed
    Score: 0.091
  9. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.057
  10. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020 04; 52(4):371-377.
    View in: PubMed
    Score: 0.056
  11. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019 05 06; 21(5):596-605.
    View in: PubMed
    Score: 0.053
  12. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 2019 04 29; 7(1):66.
    View in: PubMed
    Score: 0.053
  13. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.
    View in: PubMed
    Score: 0.052
  14. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792.
    View in: PubMed
    Score: 0.050
  15. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
    View in: PubMed
    Score: 0.049
  16. Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358.
    View in: PubMed
    Score: 0.047
  17. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 03 31; 355(6332).
    View in: PubMed
    Score: 0.046
  18. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5.
    View in: PubMed
    Score: 0.046
  19. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016 11 10; 539(7628):309-313.
    View in: PubMed
    Score: 0.044
  20. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65.
    View in: PubMed
    Score: 0.043
  21. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist. 2016 Feb; 21(2):214-9.
    View in: PubMed
    Score: 0.042
  22. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909.
    View in: PubMed
    Score: 0.037
  23. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009 Jul 15; 15(14):4622-9.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.